STUDresearch · Non-peptide

CoQ10 / Ubiquinol

Also known as

Coenzyme Q10 · ubiquinone · ubiquinol · ubidecarenone · CoQ-10 · coenzyme Q-10 · CoQH2 / CoQ10H2 (reduced form nomenclature) · Kaneka Ubiquinol (branded reduced form often cited) · Bio-Quinone / Myoqinon (trial/soft-gel ubiquinone brands discussed)

Community talk. May be wrong. Not medical advice. Not a protocol. Not for human or animal use.

Open in the directory ↗

Non-peptide Some talk Systemic Oral Longevity & cellular energy

Systemic oral fat-soluble cofactor aimed at circulating and tissue CoQ pools; not a local injectable peptide or acute stimulant.

What people say CoQ10 is an endogenous mitochondrial cofactor and membrane antioxidant sold mainly as ubiquinone or ubiquinol. Form, oil matrix and crystal dispersion can matter as much as the form name on the label. Doses people talk about

Consumer discussion~90–200 mg oral daily

Bottle and general-health range; no official universal dose was identified.

Heart-failure trials~100–400 mg/day; Q-SYMBIO 100 mg three times daily

The named Q-SYMBIO total was 300 mg/day for 2 years on top of standard care.

KiSel-10 combination200 mg/day CoQ10 + 200 mcg/day selenium

Multi-year elderly cardiovascular intervention; it cannot isolate CoQ10 from selenium.

Statin-muscle discussion~100–200 mg/day for 1–2 months

Common clinician/community n-of-1 range while the statin continues; evidence is mixed.

Statin rechallenge experiment600 mg/day ubiquinol after a 2-week preload

A high-dose controlled SAMS design that did not improve pain, strength or fitness versus placebo.

Migraine prevention~100 mg three times daily or ~300 mg/day; combinations may use 150 mg

Preventive rather than acute-abortive context; combination products also include riboflavin and magnesium.

Male-fertility studies200 or 400 mg/day oral for ~3 months

OAT studies tracked semen parameters; larger changes in some 400 mg arms do not create a universal dose rule.

Neurologic research1,200–2,400 mg/day; short studies approached ~3,000 mg/day

Specialist PD, ALS and deficiency contexts, sometimes with vitamin E; tolerability reports do not establish efficacy or a consumer default.

Rows preserve the distinct historical amounts and trial purposes without turning them into a dose ladder or claiming ubiquinone and ubiquinol are interchangeable.

Half-life & effect duration

Half-life in the body: Oral studyAbout 33 hours
Other summariesAbout 33–57 hours
Felt duration people report: Sleep reportsSleepiness or easier return to sleep in some; stimulation or insomnia in others
Longer after-effectsHeadache or lethargy into the next day, sometimes longer after stopping

Timing context & sources

How it may feel Most goals are judged over weeks, not as a stimulant hit. Inspected reports conflict sharply: 50 mg ubiquinol was linked to easier return-to-sleep in one log, while others described insomnia, daytime sleepiness, headache or next-day lethargy, sometimes changing after a form switch.

Cycles people discuss Discussion is usually continuous daily use, with evaluation windows tied to the goal: roughly 4–12 weeks for several symptom endpoints and months to years in named cardiovascular trials. This is not a peptide-style on/off cycle. Timing Common routines pair oral CoQ10 with a fat-containing meal, whether breakfast, lunch or dinner. Some people move it earlier after late-dose sleep disruption; reports are mixed and do not establish one superior morning or evening slot. Stacks Statin co-use, selenium in KiSel-style trials, and magnesium/riboflavin migraine combinations are the most concrete pairings. Multi-ingredient use makes a personal felt effect harder to attribute to CoQ10 alone. Watch for Warfarin / anticoagulant flag: Historical case-level concern that CoQ (structurally related to vitamin K) may reduce warfarin effect / alter INR; later data mixed (null, decreased effect, or rare opposite bleeding narratives) — still a standard caution with INR monitoring if used.

Tap a line to jump into the full notes. Research only — may be wrong.

Timing context & sources

Half-life in the body

A classic human tracer study measured a mean terminal elimination half-life of 33.19 hours for orally administered deuterium-labelled CoQ10 in plasma.

Sixteen healthy men received one 100 mg oral dose; mean plasma peak occurred at 6.5 hours and most participants showed a second peak near 24 hours.

This is a small 1986 single-dose study of exogenous labelled crystalline CoQ10. It does not define endogenous tissue-pool turnover or make every oil matrix, ubiquinone and ubiquinol formulation exposure-equivalent.

Tomono et al. — Pharmacokinetic study of deuterium-labelled coenzyme Q10 in man (opens in a new tab)Abstract: 16 healthy men received 100 mg oral d5-CoQ10; mean Tmax 6.5 ± 1.5 h, terminal half-life 33.19 ± 5.32 h, with a second plasma peak near 24 h in most subjects.Abstract-level review of a small 1986 single-dose study; tissue concentrations and modern formulation comparisons were not measured.
Mantle and Dybring — Bioavailability of Coenzyme Q10: An Overview of the Absorption Process and Subsequent Metabolism (opens in a new tab)Review sections on absorption, ubiquinone/ubiquinol redox conversion, oil matrices and crystal dispersion; formulation comparisons include materially lower bioavailability when crystals were not dispersed.Narrative review, not a new PK trial. Both authors are Pharma Nord employees, and named formulation examples include Pharma Nord products. Product-specific comparisons cannot establish universal brand or redox-form superiority.

Felt duration people report

The inspected reports do not establish one felt-duration window: sleepiness, easier return-to-sleep, stimulation, insomnia, headache and next-day lethargy all appeared.

One 50 mg afternoon ubiquinol poster linked easier sleep to the first nights and a deliberate skipped day. Other posters reported insomnia at 30–300 mg, symptoms into the next day or longer after stopping, and one author reported tolerating ubiquinone after adverse effects on 300 mg ubiquinol.

Unverified products, forms, doses, health conditions and co-supplements differ. Same-author skips, stops and form switches improve chronology but remain unblinded anecdotes and do not equate subjective persistence with plasma half-life.

50 mg ubiquinol fixed my middle-of-the-night insomnia — first-person thread and follow-ups (opens in a new tab)Post and OP replies: 50 mg ubiquinol in the afternoon for several weeks, sleepier first nights, easier return to sleep, worse sleep on one deliberate skipped day; later attributed better daytime mood/energy to improved sleep. Replies include opposite insomnia and daytime sleepiness.Single unblinded self-report with one skipped day, unverified product and concurrent magnesium; replies are separate people with different exposures.
Does CoQ10 make insomnia worse? — dose changes, stops and same-author follow-ups (opens in a new tab)Post and comment chains: 100 mg with worsening insomnia; 300 mg helped migraine/energy but halved sleep; a 100-to-30 mg same-author change still caused insomnia; another chain reports stabilization after stopping and improvement after about one week off.Products, forms and co-supplements are unverified; commenters are heterogeneous, timing is recalled rather than measured, and causal withdrawal language is not clinically adjudicated.
CoQ10 makes me feel awful — form switch and adverse-duration follow-ups (opens in a new tab)OP and edits: 300 mg ubiquinol daily for about two weeks with lethargy, headache and sinus pressure into the next day; later reported no such symptoms on an average dose of ubiquinone. Other same-author chains report symptoms resolving over days to weeks after stopping.Unverified formulations and doses, no blinded rechallenge or laboratory attribution; comments include speculative mechanisms and must not be treated as measured clearance.

Other context in this card

Institute for Natural Medicine — CoQ10 fact sheet, dose-recommendation context (opens in a new tab)Dose Recommendations section, paragraph beginning with maintenance of blood/plasma levels (rendered line 272): approximately 1–1.2 mcg/mL, at least 200 mg/day, preferably with food in two or three divided doses. Page updated June 29, 2026.Practitioner fact sheet, not regulator labeling, a universal plasma target or a primary PK trial. Used only to identify the source of the preserved plasma-maintenance discussion, not to prescribe a dose or endorse the page's other claims.

What people say 14

Subjective energy: Multi-week steadier energy / less “flat” feel common in forums and mito stacks; confounded by sleep, iron, thyroid, training, and co-supplements. forum
Exercise / athletes: Recovery and “mito stack” anecdotes common; single-agent performance proof weaker than multi-nutrient or training-block confounds. forum
Ubiquinol preference lore: Older adults and “poor converters” threads favor reduced form for higher plasma; independent reviews stress formulation (crystal dispersion, oil matrix) can flip relative bioavailability vs bulk crystalline ubiquinone. forum
Heart-failure adjunct (Q-SYMBIO): Moderate–severe HF patients randomized to CoQ10 100 mg three times daily (300 mg/day total) vs placebo for 2 years on top of standard therapy — primary short-term endpoints at 16 weeks plus longer MACE/mortality signals widely cited in CV/supplement discourse. trial
Elderly Se + CoQ (KiSel-10 / KISEL-10): Independently living elderly (~70–88) given ~200 mg/day CoQ10 (e.g., Bio-Quinone 100 mg soft-gels) + ~200 mcg/day selenium yeast vs placebo for ~4 years — better cardiac function markers, QoL, fewer hospitalizations, and ~50% relative CV-mortality reduction signals in primary reports; 10–12 year follow-ups still discuss lower CV death rates after intervention stopped. trial
Blood pressure (meta): Cardiometabolic meta-analyses report modest systolic BP reductions (~3–5 mmHg class; one GRADE-assessed review ~−4.8 mmHg SBP with circulating CoQ rise); U-shaped dose-response talk often peaks benefit around ~100–200 mg/day for SBP; DBP signals weaker/inconsistent. trial
Statin muscle comfort — mixed: Community and older small trials often claim less mild–moderate myalgia at ~100–200 mg/day; Harvard-style clinical summaries note low risk of a 1–2 month trial at those doses despite unconvincing proof. trial
Statin myalgia high-dose null: Confirmed SAMS crossover designs using ubiquinol 600 mg/day (2-week load then 8 weeks with simvastatin) failed to beat placebo on pain, strength, or aerobic fitness despite large serum CoQ rises — frequently cited as the strongest negative study. trial
Migraine prevention: Studied as preventive (not acute abortive); typical discussed bands ~100 mg TID or ~300 mg/day; fixed combos with magnesium + riboflavin (e.g., ~400 mg B2 / ~600 mg Mg / ~150 mg CoQ10 in Dolovent/Migravent-class products) show migraine-day and intensity signals in multicenter work. trial
Male fertility / OAT: Open and controlled work at 200 mg/day or 400 mg/day oral (often ubiquinol) for ~3 months reports better sperm concentration, progressive motility, and seminal antioxidant enzymes; 400 mg arm often outperforms 200 mg on several parameters. trial
Fertility combo talk: CoQ10 200 mg + L-carnitine ~1 g/day multi-month designs discussed as superior to either alone for idiopathic OAT semen parameters in some RCTs. trial
Aging tissue CoQ: Tissue CoQ declines with age in literature; oral raise of plasma is clear, organ uptake dose/organ-dependent (atrial tissue rise shown pre-cardiac surgery at high dose; skeletal muscle uptake less consistent). trial
Neuro high-dose research: Early PD dose-escalation safety work up to multi-gram/day; large phase 3 QE3 (1200 or 2400 mg/day + vitamin E 1200 IU) was well tolerated but showed no clinical benefit on early PD progression — futility stop. trial
Safety ceiling narrative: Multi-year use of multi-hundred mg and short/medium trials at 1,200–2,400 mg/day (and limited work toward ~3,000 mg/day) generally report good tolerability; plasma plateaus discussed near very high oral intakes. trial

Doses people talk about 21

Consumer wellness band: Often ~90–200 mg oral daily on bottles and forum “general health” charts. forum
UK/general-supplement talk: ~100–200 mg/day commonly cited where no official national dose exists. forum
Statin-myalgia community/clinician trial range: Commonly ~100–200 mg/day for a 1–2 month n-of-1 trial while statin continues. forum
Uncertainty flag: Bottle mg, oxidized vs reduced label, and third-party assay quality are not interchangeable for plasma rise or symptom effect. forum
Cardiac / HF trial band: Often ~100–400 mg/day total oral; Q-SYMBIO used 100 mg three times daily = 300 mg/day for 2 years. trial
KiSel-10 longevity/CV elderly: 200 mg/day CoQ10 + 200 mcg/day selenium for multi-year intervention. trial
BP meta sweet-spot talk: U-shaped SBP response discussed with approximate greatest benefit around ~100–200 mg/day in cardiometabolic cohorts. trial
Migraine preventive: ~100 mg three times daily (300 mg/day total) widely listed; some sources cite ~300 mg once-daily class; combo products often use ~150 mg CoQ10 with 400 mg riboflavin + 600 mg magnesium. trial
Male fertility: 200 mg/day or 400 mg/day oral for ~3 months common in OAT studies; higher dose often larger semen-parameter deltas. trial
Split dosing: Totals above ~100–200 mg frequently split 2–3×/day with meals — Q-SYMBIO TID logic and absorption-saturation talk (large single boluses can underperform split intake). trial
With dietary fat: Fat-soluble — take with a fat-containing meal or oil-based soft-gel; empty-stomach dry powder is repeatedly blamed for “no effect.” trial
Ubiquinol vs ubiquinone dose culture: Marketing and older-adult lore say ubiquinol raises plasma more or lets you use a somewhat lower mg; Lopez-Lluch-style head-to-heads and Mantle reviews argue best ubiquinone soft-gels can match or beat ubiquinol depending on matrix — clinical outcome superiority unsettled. trial
Oral bioavailability reality: Often cited that only a few percent of crystalline oral CoQ reaches circulation; plasma rises are real but tissue delivery is organ- and dose-dependent. trial
Liposomal / enhanced oral marketing: Liposomal CoQ products claim higher Cmax/AUC vs standard in small PK studies; treat as formulation claims until broadly replicated. trial
Framing: Trial and community discussion ranges only — not medical advice, not prescriptions. forum
Dietary vs supplemental gap: Food CoQ is low mg-scale; capsule labels are tens–hundreds of mg — research discussion, not “food equivalent.” trial
Plasma-maintenance talk: Some clinical fact sheets argue ≥~200 mg/day (split 2–3× with food) to keep plasma in a “normal” ~1–1.2 mcg/mL class range — interpretive, not universal labeling. trial
Statin-myalgia high experimental arm: 600 mg/day ubiquinol (often as 300 mg × 2 soft-gels) with 2-week preload before statin rechallenge in definitive negative SAMS RCT. trial
Neuro / deficiency experimental: 1,200–2,400 mg/day in PD phase 2/3 designs (with vitamin E 1,200 IU in QE protocols); short escalations toward ~3,000 mg/day in ALS/safety pilots; primary CoQ deficiency literature discusses high pharmacologic mg and pediatric mg/kg — specialist territory, not consumer default. trial
Upper safety narrative: Reviews cite well-designed RCT comfort often through ~1,200 mg/day; higher multi-gram use short-term tolerated in neuro trials; one secondary source notes ~2,400 mg/day × 5 years and ~1,500 mg/day ubiquinol × 48 weeks as reported safe windows in specific contexts. trial
Formulation > label mg: Soft-gel oil matrices and thermal crystal dispersion of ubiquinone can change AUC several-fold; poorly dispersed crystalline material cut bioavailability ~75% in comparative work. trial

How it may feel 8

Acute (hours): No stimulant kick for most; Cmax is hours later, not minutes. Minority get mild GI if large empty-stomach dose. forum
Days 1–7: Plasma starts rising; subjective energy usually still flat. Occasional heartburn/nausea at high single boluses. forum
Weeks 2–4: Common first reassess for statin myalgia trial or “do I feel anything?” — forums also re-check take-with-fat and form. forum
Months 3–6: Continuous daily use feels like background support rather than escalating sensation; fertility and CV adjunct talk often lives here. forum
No change by ~4–8 weeks: Community troubleshooting — fat-containing meal, split dose, soft-gel quality, ubiquinol trial, goal mismatch (e.g., expecting stimulant energy or acute migraine abort). forum
Weeks 1–2: Steady-state plasma typically approached (~1–2 weeks of daily dosing); early energy or statin-comfort anecdotes begin or never appear. trial
Weeks 4–12: Matches many CV short endpoints, migraine preventive windows (~8–12 weeks often cited), fertility 3-month semen rechecks, and BP meta subgroups favoring >12-week arms. trial
Years (elderly Se+CoQ culture): KiSel-style multi-year daily use; benefit framed as CV risk reduction, not a daily “feel.” trial

Cycles people discuss 8

Continuous daily culture: Treated as an ongoing daily nutrient-style supplement, not short pulsed peptide on/off cycles. forum
Statin co-use habit: Often indefinite while the statin continues — community/clinician pragmatism, not a formal approved protocol. forum
Time-off: Budget, travel, or “do I still need it?” pauses appear; no standard washout ritual for efficacy. forum
Re-starts: Routine after gaps; less ritualized than SARMs/GH secretagogues. forum
Eval window: 4–12 weeks matches many human blocks (statin comfort n-of-1, migraine preventive, short CV endpoints, fertility 3-month semen checks). trial
HF / elderly CV adjuncts: Multi-month to multi-year continuous use in Q-SYMBIO and KiSel designs. trial
Load then maintain (statin research design only): SAMS trial preloaded 600 mg/day for 2 weeks before statin reinitiation — research maneuver, not consumer default. trial
Migraine fair trial: Often ~8–12 weeks before judging frequency reduction. trial

Timing 9

With-meal timing: With largest fat meal (breakfast or dinner) is common; AM vs PM superiority data thin; migraine stack charts often put CoQ with a fatty lunch/dinner. forum
Insomnia anecdotes: Minority report late-dose sleep disruption — forums sometimes move dose earlier; confounded and uncommon relative to GI complaints. anecdote
Feel lag: Energy, muscle comfort, migraine frequency, or fertility lab changes — if any — track over weeks, not minutes post-capsule. forum
Plasma half-life: ~33 hours after absorption (deuterium-labeled crystalline CoQ classic PK); secondary sources sometimes quote a wider ~33–57 hour band. trial
Time to peak (Cmax): Typically ~6 hours post oral dose; broader formulation/food window often ~5–10 hours. trial
Second plasma peak: Some studies note a smaller second peak ~24 hours — framed as enterohepatic recycling / redistribution from liver. trial
Steady state: ~1–2 weeks of consistent daily dosing for plasma steady state; tissue steady-state talk often extends to ~2–4 weeks. trial
Daily dosing logic: Long half-life supports once or twice daily oral — not weekly depot peptide logic; TID used in Q-SYMBIO for absorption/saturation reasons more than ultra-short half-life. trial
Tissue vs plasma: Plasma CoQ rises reliably; heart muscle vs skeletal muscle uptake differs by study and dose; healthy-tissue saturation limits are debated. trial

Stacks 10

Statin co-stack: Most named practical pairing in consumer health — CoQ while continuing statin for myalgia lore despite mixed RCTs. forum
Classic mito pair — PQQ + CoQ10: Community and some combo trials discuss PQQ ~10–20 mg/day with CoQ ~100–300 mg/day (e.g., 20 mg PQQ + 200 mg CoQ fatigue/performance talk). forum
Broader mito longevity blend: CoQ + ALA + ALCAR ± NMN/NR ± urolithin A — shopping-list stacks more than single RCT arms. forum
CV multi-nutrient: Omega-3 fish oil, magnesium, and CoQ co-listed in heart-health forums. forum
Vs MitoQ / SS-31 talk: Mitochondria-targeted quinone analogs and peptides discussed as “next layer” beyond plain CoQ in biohacker threads. forum
Lifestyle confounds: Sleep, zone-2, resistance training, iron/thyroid status repeatedly credited when “energy” improves on a mito stack. forum
KiSel-style Se + CoQ: ~200 mcg selenium (often selenized yeast) + ~200 mg CoQ10 daily — multi-year elderly CV mortality narrative. trial
Migraine mitochondrial nutraceutical stack: Magnesium ~400–500 mg/day + riboflavin (B2) 400 mg/day + CoQ10 ~100–300 mg/day; fixed commercial combos use ~150 mg CoQ with 400 mg B2 + 600 mg Mg. trial
Male fertility antioxidant panel: CoQ10 200–400 mg ± L-carnitine ~1 g ± other antioxidants (vitamin E/C, zinc, etc.) for OAT programs — evidence quality varies by agent. trial
Neuro research co-admin: High-dose CoQ trials sometimes fixed vitamin E (e.g., 1,200 IU/day in QE PD protocols) — historical trial design, not a consumer mandate. trial

Storage notes 2

No mix instructions here: STUDresearch does not list reconstitution, diluent volumes, or syringe unit charts. People reconstitute many different ways and vial labels differ — that content creates more confusion than clarity. forum
Storage (general talk only): Unopened research products are usually kept cool, dry, and away from light per the seller label. Anything after first use is product-specific — follow the label, not a universal forum SOP. forum

Related 8

Watch for 13

Insomnia / stimulation anecdotes: Minority report sleep disruption with late dosing; often confounded by caffeine/stackmates. anecdote
Chemotherapy / diabetes meds: Secondary sources flag interaction uncertainty with some chemo agents and glucose-lowering drugs; medical-domain, not forum self-protocol. forum
Statin decision risk: Using CoQ to “push through” severe myopathy, dark urine, or weakness without medical evaluation can delay recognition of serious statin injury. forum
Product quality / oxidation: Under-dosed labels, form swap (ubiquinone sold as ubiquinol), heat-damaged soft-gels, and no third-party assay are practical risks separate from molecule pharmacology. forum
Not a care substitute: Do not self-manage chest pain, decompensated HF, uncontrolled hypertension, or severe statin symptoms with OTC CoQ alone. forum
Generally well tolerated: Favorable short- and multi-year safety at typical study doses (hundreds of mg) and even multi-gram neuro-trial exposures; still not risk-free for every person or every drug combo. trial
GI effects: Nausea, heartburn/epigastric discomfort, belly pain, diarrhea/loose stools — more common at high single doses or empty stomach; split-with-food is the usual community fix. trial
Other mild reports: Headache, dizziness, rash, appetite change, or light sensitivity appear in secondary lists at low frequency. trial
Blood pressure additive effect: Modest SBP-lowering meta-signals → theoretical extra drop when combined with antihypertensives (ACEI/ARB/BB/CCB/diuretics) — monitor talk in consumer safety sheets. trial
Warfarin / anticoagulant flag: Historical case-level concern that CoQ (structurally related to vitamin K) may reduce warfarin effect / alter INR; later data mixed (null, decreased effect, or rare opposite bleeding narratives) — still a standard caution with INR monitoring if used. trial
Pregnancy / lactation: Limited high-quality safety data — conservative exclusion outside supervised settings is common guidance language. trial
Neuro high-dose ≠ consumer mandate: Multi-gram PD/HD trial doses were research protocols with safety monitoring; null efficacy in large PD progression work undercuts “more is better for brain” lore. trial
Long-term healthy-user gap: Multi-year data densest in elderly Se+CoQ and HF adjunct trials — lifelong high-dose biohacker use still thinner on hard outcomes. trial

Updated: 2026-08-12

Evidence mix More trial/lab tags than forum tags Full: every bullet (trial + community). Use Scan for a faster bro-science read.

↑ Back to top

Half-life & effect duration

Timing context & sources⌄

Half-life in the body

Felt duration people report

Other context in this card

What people say 14

Doses people talk about 21

How it may feel 8

Cycles people discuss 8

Timing 9

More on what it is 7

Stacks 10

Storage notes 2

Related 8

Watch for 13

Timing context & sources